Posted by Michael Wonder on 02 Jun 2022
Eagle Pharmaceuticals announces submission of new drug application to US FDA for landiolol, a beta-1 adrenergic blocker
1 June 2022 - Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
Eagle Pharmaceuticals today announced that AOP Orphan Pharmaceuticals, with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application to the U.S. FDA for landiolol, a short-acting, intravenous cardio-selective beta-1 adrenergic blocker.
